Commentary (Seidman/Kurman): Update on Low Malignant Potential Ovarian Tumors
نویسندگان
چکیده
The borderline category of ovarian tumors is one of the most controversial topics in gynecologic oncology and pathology, and is confusing to both clinicians and patients. Although numerous reviews have appeared in the literature, most of them rehash the prevailing views on borderline tumors without critically evaluating the published data that allegedly validate some rather puzzling and perplexing notions. For example, although these tumors are considered to be a subset of carcinoma, most patients are cured even when they have “metastatic” disease that has been inadequately treated. In addition, reports cite recurrence and death as late as 39 years after the diagnosis of tumors that appear histologically bland and noninvasive.
منابع مشابه
Commentary (Trimble/Trimble): Update on Low Malignant Potential Ovarian Tumors
Nomenclature Various names have been applied to this entity. These include “ovarian tumors of low malignant potential,” “borderline ovarian tumors,” “atypical proliferating ovarian tumors,” and even “borderline ovarian carcinomas.” Each of these terms has its drawbacks. “Low malignant potential” suggests that these tumors have a certain propensity to become malignant. In fact, as Kurman and Tri...
متن کاملMolecular pathogenesis of ovarian borderline tumors: new insights and old challenges.
Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and thei...
متن کاملMutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) ...
متن کاملSimultaneous carcinomas involving the endometrium and ovaries
20. Fujii S, Konishi J, Kobayashi F. Sarcoma-like mural nodules combined with a microfocus ofanaplastic carcinoma in mucinous ovarian tumor. Gynecol Oncol 1985; 20: 219-233. 21 . Prst J. Sarcoma-like mural nodules in mucinous cystic tumors of the ovary. Modern Pathol 1997; 10:107 (Abst.). 22. Pettersson F. Annual Report of the Results of Treatment in Gynecological Cancer. International Federati...
متن کاملDiagnostic potential of tumor DNA from ovarian cyst fluid
We determined whether the mutations found in ovarian cancers could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non-neoplastic cysts...
متن کامل